Quarterly report [Sections 13 or 15(d)]

Note 7 - Stockholder's Equity (Tables)

v3.26.1
Note 7 - Stockholder's Equity (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]
   

Number of

   

Weighted

 
   

Units and

   

Average Grant

 
   

Awards

   

Date Fair Value

 

Unvested balance at December 31, 2025

    235,400     $ 3.19  

Vested

    (200 )     85.50  

Unvested balance at March 31, 2026

    235,200     $ 2.53  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
                   

Weighted

         
                   

Average

         
           

Weighted

   

Remaining

   

Aggregate

 
   

Number

   

Average

   

Contractual

   

Intrinsic Value

 
   

of Options

   

Exercise Price

   

Term (years)

   

(in thousands)

 

Outstanding at December 31, 2025

    256,474     $ 9.74       8.6     $  

Outstanding at March 31, 2026

    256,474     $ 9.74       8.4     $  

Expected to vest

    81,950     $ 6.46       8.4     $  

Exercisable

    174,524     $ 11.27       8.4     $  
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
   

For the Three Months Ended

 
   

March 31,

 
   

2026

   

2025

 

Research and development

  $ 14     $ 40  

General and administrative

    47       145  

Total stock-based compensation expense

  $ 61     $ 185  
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
           

Weighted

         
           

Average

   

Aggregate

 
           

Exercise

   

Intrinsic Value

 
   

Warrants

   

Price

   

(in thousands)

 

Outstanding, December 31, 2025

    772,741     $ 10.56     $  

Expired

    (10 )     0.11        

Outstanding, March 31, 2026

    772,731     $ 10.56     $